大家乐彩票开户



歐陽文章:直銷立法要正

歐陽文章:直銷立法要正

XINJINGJISHIDAIYAOJIAKUAIZHIXIAOLIFADEBUFA,ZHESHIZHIXIAOXINGYEDEYIGEJIBENGONGSHI。BIZHERENWEI,DANGQIANSHI

李惠森:永遠不變的就是

李惠森:永遠不變的就是

大家乐彩票开户1YUE4RI,YI“XINSHENGTAI XINBUJU XINWEILAI”WEIZHUTIDE2020WUXIANJIQUANQIULINGDAORENNIANHUIJIWUWUFAZHANJI

韓金明新年祝福:為實現

韓金明新年祝福:為實現

大家乐彩票开户2020NIANLAILINZHIJI,WODAIBIAOHEZHIYOUDEDONGSHIHUI,DUIYIZHIYILAIGUANXIN、AIHUHEZHIYOUDEDESHEHUIGEJIEPENG

當前位置: 直銷報道網 > 企業 >

以嶺藥業榮獲國家科技進步一等獎

時間:2020-01-10 16:44來源:財經快報網 作者:財經快報網 點擊:
2020年1月10日,2019年度國家科學技術獎勵大會在北京人民大會堂隆重召開。由中國工程院院士吳以嶺作為第一

【直報網北京1月10日訊】(財經快報網)2020年1月10日,2019年度國家科學技術獎勵大會在北京人民大會堂隆重召開。由中國工程院院士吳以嶺作為第一主研人完成的“中醫脈絡學說構建及其指導微血管病變防治”獲得了2019年度國家科技進步一等獎,這是該年度醫藥衛生界唯一的國家科技進步一等獎,也是以嶺藥業自2000年以來獲得的第六項國家科學技術獎。

獲獎項目三大創新惠及四千萬患者

大家乐彩票开户 YILINGYAOYEHUODEDEJIANGXIANGZHONG,JIYOUZHONGYILILUNYUANCHUANGXINGYANJIUCHENGGUO,YOUYOUZHONGYAOSHENGCHANGONGYIDEZHONGDACHUANGXINXIANGMU,HUANYOUZHONGYAOXINYAOFANGZHIZHONGDAJIBINGDETUPO。TANJIBENCIHUOJIANG,WUYILINGYUANSHIZHICHU:“BENCIHUOJIANGDEXIANGMU,FENBIECONGLILUN、JIZHI、LINCHUANGSANGEFANGMIANKAIZHANYANJIUBINGQUDELETUPO,GONGYOUSANDACHUANGXINDIAN。”YISHIXITONGGOUJIANLEZHIDAOWEIXUEGUANBINGBIANFANGZHIDEMOLUOXUESHUO,SHUYUZHONGYIYAOXUESHUYANJIUDEZHONGDALILUNYUANCHUANGCHENGGUO;ERSHIGAIYANJIUCHANMINGLEYANZHONGWEIHAIRENLEIJIANKANGDEXINNAOXUEGUANJIBINGJITANGNIAOBINGSHENBINGDENGNANZHIXINGJIBINGFABINGDEGONGXINGJIZHISHIWEIXUEGUANBINGBIAN,ERBAOHUWEIXUEGUANNEIPIXIBAOZESHIZHILIAOWEIXUEGUANBINGBIANDEHEXINJIZHI,GUOJIA973JIHUAXIANGMUYANSHOUZHUANJIAZUYIZHIRENWEIGAIXIANGMU“QUDELEZHONGYIYAOZHILIAOWEIXUEGUANBINGBIANZHONGDATUPO”;SANSHIGAIXIANGMULIYONGGUOJIGONGRENDEXUNZHENGYIXUEYANJIUFANGFAKAIZHANLEDALIANGLINCHUANGSHIYANJIEJUELEGUOJIYIXUEJIEZHONGDANANTI——TONGXINLUOJIAONANGJIEJUELEJIXINGXINGENGWUZAILIUSHIJIEYIXUENANTI;CANSONGYANGXINJIAONANGWEIXINGONGNENGBUQUANBANSHIXINGZAOBOZHILIAOTIGONGLEXINYAOWU,TIANBULEDOUXINGXINDONGGUOHUANBANSHIXINGZAOBOKUAIMANJIANZHI、ZHENGHEDIAOLVDEYAOWUZHILIAOKONGBAI;QILIQIANGXINJIAONANGMINGXIANTIGAOLEMANXINGXINLISHUAIJIELINCHUANGZHILIAOXIAOGUO。GUOJIA973JIHUAXIANGMUYANSHOUZHUANJIAZUCHENG:BENYANJIU“CHUANGLILE‘LILUN+LINCHUANG+XINYAO+SHIYAN+XUNZHENG’YITIHUADEZHONGYIXUESHUCHUANGXINYUZHUANHUAXINMOSHI,ZHONGYICHUANTONGLILUNCHUANGXINYUXIANDAIKEXUEJISHUXIANGJIEHE,CHANSHENGZHONGDAYUANCHUANGCHENGGUO,WEIZHONGYIYAOCHUANCHENGYUCHUANGXINFAZHANZUOCHULESHIFAN”。

大家乐彩票开户 “ZHONGYIMOLUOXUESHUOGOUJIANJIQIZHIDAOWEIXUEGUANBINGBIANFANGZHI”XIANGMUYANJIUHUODEGUONEIWAIYIXUEJIEGAODUPINGJIA,TUIDONGZHONGYIYAOXUESHUGUOJIHEZUOJIGUOJIHUAJINCHENG,QUDELEXIANZHUDESHEHUIXIAOYI。WUYILINGYUANSHIBIAOSHI:“GAIYANJIUXIANGMUJIESHILETONGLUOYAOWUDEKEXUEJIAZHI,BEIYIXUEJIECHENGWEI‘TONGLUOSANBAO’DETONGXINLUO、CANSONGYANGXIN、QILIQIANGXINJIAONANGJINSANNIANXIAOSHOUEDA87.03YIYUAN,SHANGJIAOSHUIJIN11.41YIYUAN,YUE4350WANRENCIFUYONGSHOUYI,SHEHUIJINGJIXIAOYIXIANZHU。”

持續創新是六獲大獎的硬核驅動力

YILINGYAOYEZHISUOYINENGLIUHUOGUOJIADAJIANG,GUANJIANZAIYUTAMENSHIZHONGBACHUANGXINZUOWEIQIYEDEHEXINJINGZHENGLI。YILINGYAOYEYOUZHONGGUOGONGCHENGYUANYUANSHIWUYILINGJIAOSHOUYU1992NIAN6YUE16RICHUANGBAN,BA“JICHENGCHUANGXIN,ZAOFURENLEI”ZUOWEIQIYEZONGZHI,SHIZHONGYINGZAOYOULIYUCHUANGXINDEWENHUAFENWEI,QIYEZISHANGERXIAMEIGEXIBAODOUCHONGMANZHUCHUANGXIN,CHUANGXINWENHUAYOULIDIJIFAQIYEDEHUOLI,HUANQIQIANGDADENENGLIANG、REQING、ZHUDONGXINGHEZERENGAN。JINGGUO20YUNIANDEFAZHAN,YILINGYAOYELAOGUGAOZHILIANGFAZHANLINIAN,ZAITIZHICHUANGXIN、LILUNCHUANGXIN、KEJICHUANGXIN、CHANPINCHUANGXIN、JISHUCHUANGXINDENGFANGMIANLEIJIESHUOGUO,LIUHUOGUOJIADAJIANG。

TIZHICHUANGXIN,YILINGYAOYECHUANGLILE“LILUN-LINCHUANG-KEYAN-CHANYE-JIAOXUE”WUWEIYITIDEDUTEFAZHANMOSHI,ZAIQIYENEIBUJIANGCHANXUEYANWANMEIRONGWEIYITI,JINGGUO20YUNIANDEFAZHAN,RANGYILINGCONGYIGEXIAOYANJIUSUOCHENGCHANGWEIZHONGGUOYIYAOSHANGSHIGONGSI20QIANGQIYE,BINGQIEZHEYITIZHICHUANGXINYUELAIYUEXIANSHICHUCUJINGAOXINJISHUCHENGGUOZHUANHUAWEISHENGCHANLIDEJUDAYOUYUEXING。

理論創新,吳以嶺院士帶領團隊集中在中醫學術體系的獨特組成部分絡病理論的創新發展上開展研究,系統構建了絡病證治、脈絡學說、氣絡學說三大理論體系,建立以中醫絡病理論創新為指導的新藥研發技術體系,凝聚包括海歸博士、外籍專家等一大批高水平科技人才,建立了院士工作站,我國30位生物醫藥兩院院士入站,建立了復方中藥、組分中藥、單體中藥的高水平研發平臺,形成了中藥創新藥、化學一類新藥、國際制劑的研發格局,先后承擔和完成了國家973、863,國家“十一五”支撐、國家重大新藥創制等國家級重大項目30余項,研發專利新藥10余個,取得發明專利570余項。“中醫脈絡學說構建及其指導微血管病變防治”“絡病理論及其應用研究”分別榮獲國家科技進步一等獎和二等獎。

頂一下
(0)
0%
踩一下
(0)
0%
分享到:
------分隔線----------------------------
發表評論
請自覺遵守互聯網相關的政策法規,嚴禁發布色情、暴力、反動的言論。
評價:
?
關于我們 | 聯系我們 | 誠聘英才 | 服務條款 | 廣告服務 | 頻道合作 | 本網內容授權書
Copyright ? 1998 - 2013 rajivweb.com All Rights Reserved
直銷報道網 © 版權所有